Where there is inflammation, treatment may reduce disability progression -No Gilles Edan and Sandra Vukusic
The respective weight of and the interplay between inflammatory and neurodegenerative components are highly variable in multiple sclerosis (MS), depending of age, disease duration, mainly of the clinical phase of the disease, relapsing-remitting, or progressive. As a consequence, the reduction of inflammation with disease modifying drugs (DMD) might have a highly variable impact on disability worsening, depending of the timing of their use, much better documented in the early phase of the disease, controversial at more advanced stages.
Natural history studies provided converging arguments that suggest relapses may not be a so important player in accumulation of disability in the long-term. In the early 2000s, the analysis of the Lyon EDMUS cohort 1 showed that once a clinical threshold of irreversible disability has been reached, the subsequent progression of disability was not affected by relapses, either those that occur before the onset of the progressive phase or those superimposed during this phase. Furthermore, clinical variables that were assessable early in the disease, including the number of relapses in the first 5 years, were predictors of the time from disease onset to the onset of irreversible disability, but not of the later stages. 2 Those initial results are in line with the findings of the London Ontario group, 3 showing that the progressive course of the disease was independent of the presence of no, one, or several relapses before onset of progression. In addition, the number of relapses experienced during the late relapsing-remitting phase (from year 3 to SPMS onset) did not show any deleterious effect on the key outcomes of secondary progression or on time to DSS 6, 8 or 10, highlighting two distinct disease phases related to disability worsening but separated by a watershed within the RR phase. 4 Similarly, in the Rennes EDMUS cohort, 5 the time from clinical onset to DSS3 was found to be clearly independent of the time from DSS3 to DSS6, and in relapsing onset MS, residual deficit after the first relapse and relapses during the first 2 years of MS were found to be independent predictors of disability progression during the early phase of the disease (between clinical onset and irreversible DSS3) and not in a later phases of disability progression (between irreversible DSS3 and DSS6), pointing out that MS disability worsening could follow a two-stage process, with a first stage probably highly related to focal inflammation and a second stage mostly independent of current or preceding focal inflammation. It was also observed that relapses, decreasing with patients' age and disease duration, 6 had no influence on disability worsening 5 years after progression onset, 7 but still may influence short-term disability progression during the early SPMS phase. 8 Randomized clinical trials (RCTs) have also shown some dissociation between relapse suppression and disability accumulation in secondary progressive multiple sclerosis (SPMS) or primary progressive multiple sclerosis (PPMS): failure of first-line therapies in progressive MS, interferon beta 1a and 1b [9] [10] [11] [12] in SPMS, glatiramer acetate 13 in PPMS; similarly, failure of second-line therapies, rituximab 14 and fingolimod 15 in PPMS, natalizumab 16 in SPMS. Although they reduced strongly the accumulation of focal inflammatory lesions in the CNS (relapse rate, magnetic resonance imaging (MRI) activity), they had no documented impact on disability worsening at 2-3-year follow-up. Two drugs have showed, compared to placebo, a significant but limited impact on disability worsening in progressive MS: ocrelizumab 17 in PPMS and siponimod 18 in SPMS. Both rather included progressive MS patients in their early stage of progression (age <50 years, duration of the progressive phase <5 years), that is, patients at risk of still having a higher level of focal accumulation of inflammatory lesions. By contrast, the impact of these drugs on disability worsening was not documented in late progressive MS patients (i.e. age >50 years and duration of the progressive phase >5 years), an MS patient subgroup that was poorly included in these trials. In two other large phase 3 PPMS trials that included older progressive MS patients using quite similar drugs, rituximab 14 and fingolimod 15 , both drugs failed to demonstrate a positive impact on disability progression. This result suggests that there is indeed a limited impact of treating inflammation on early accumulation of disability, but could also very much be confounded by the differential efficacy of the compared drugs on relapses and MRI activity, 19 leading to a biased measure of disability progression. 19, 20 It is also important to point out that RCTs are too short to evaluate the impact of an early treatment on the appearance of the secondary progressive phase in the longer term. That does not preclude that a protective effect of DMD on inflammation would have any impact on later disability progression.
Real world evidence data are currently our only way to approach the long-term impact (several decades) of anti-inflammatory drugs on prevention of long-term disability. Observational studies have been done to evaluate the long-term impact of interferon beta suggesting that an early and sustained treatment reduces the risk of long-term disability progression in RRMS. 21, 22 There are however many methodological limitations, the most important being the poor exhaustivity of collected data and the indication bias that cannot be fully compensated by propensity score matching (unmeasurable confounding factors, especially the usual lack of good MRI data). Hopefully, these hurdles could be overcome in a near future with the development of multiparametric and systematic collections of data in national or international MS registries.
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